Fuller & Thaler Asset Management Inc. Makes New Investment in Hologic, Inc. (NASDAQ:HOLX)

Fuller & Thaler Asset Management Inc. acquired a new position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 22,665 shares of the medical equipment provider's stock, valued at approximately $1,634,000.

A number of other large investors also recently added to or reduced their stakes in the stock. General Partner Inc. acquired a new stake in shares of Hologic during the 4th quarter worth approximately $26,000. Venturi Wealth Management LLC grew its stake in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 260 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares in the last quarter. Finally, Smithfield Trust Co grew its stake in shares of Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 400 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Down 1.6 %

Shares of HOLX traded down $0.95 during mid-day trading on Thursday, reaching $57.25. 543,434 shares of the stock traded hands, compared to its average volume of 1,971,937. The firm has a market cap of $12.85 billion, a price-to-earnings ratio of 18.09, a P/E/G ratio of 2.14 and a beta of 0.82. The stock has a fifty day simple moving average of $60.66 and a 200 day simple moving average of $69.62. Hologic, Inc. has a 12-month low of $55.89 and a 12-month high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on HOLX. Morgan Stanley dropped their price target on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Argus downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Needham & Company LLC cut shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective for the company. in a research report on Monday, February 3rd. Leerink Partnrs cut shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Finally, Citigroup reduced their price target on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Hologic currently has a consensus rating of "Hold" and a consensus price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.